JP2021515032A - 好中球調節物質と免疫チェックポイントの調節物質の組み合わせを使用したがん処置 - Google Patents

好中球調節物質と免疫チェックポイントの調節物質の組み合わせを使用したがん処置 Download PDF

Info

Publication number
JP2021515032A
JP2021515032A JP2020566524A JP2020566524A JP2021515032A JP 2021515032 A JP2021515032 A JP 2021515032A JP 2020566524 A JP2020566524 A JP 2020566524A JP 2020566524 A JP2020566524 A JP 2020566524A JP 2021515032 A JP2021515032 A JP 2021515032A
Authority
JP
Japan
Prior art keywords
cancer
antibody
met
subject
biomarker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020566524A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021515032A5 (enExample
Inventor
レドゥカ，サンジーヴ
レディ，マンマサ
Original Assignee
アポロミクス インコーポレイテッド
アポロミクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アポロミクス インコーポレイテッド, アポロミクス インコーポレイテッド filed Critical アポロミクス インコーポレイテッド
Publication of JP2021515032A publication Critical patent/JP2021515032A/ja
Publication of JP2021515032A5 publication Critical patent/JP2021515032A5/ja
Priority to JP2023173684A priority Critical patent/JP2024009886A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2020566524A 2018-02-17 2019-02-17 好中球調節物質と免疫チェックポイントの調節物質の組み合わせを使用したがん処置 Pending JP2021515032A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023173684A JP2024009886A (ja) 2018-02-17 2023-10-05 好中球調節物質と免疫チェックポイントの調節物質の組み合わせを使用したがん処置

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862631771P 2018-02-17 2018-02-17
US62/631,771 2018-02-17
US201862757729P 2018-11-08 2018-11-08
US62/757,729 2018-11-08
PCT/US2019/018377 WO2019161320A1 (en) 2018-02-17 2019-02-17 Cancer treatment using combination of neutrophil modulator with modulator of immune checkpoint

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023173684A Division JP2024009886A (ja) 2018-02-17 2023-10-05 好中球調節物質と免疫チェックポイントの調節物質の組み合わせを使用したがん処置

Publications (2)

Publication Number Publication Date
JP2021515032A true JP2021515032A (ja) 2021-06-17
JP2021515032A5 JP2021515032A5 (enExample) 2022-03-09

Family

ID=67620025

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020566524A Pending JP2021515032A (ja) 2018-02-17 2019-02-17 好中球調節物質と免疫チェックポイントの調節物質の組み合わせを使用したがん処置
JP2023173684A Pending JP2024009886A (ja) 2018-02-17 2023-10-05 好中球調節物質と免疫チェックポイントの調節物質の組み合わせを使用したがん処置

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023173684A Pending JP2024009886A (ja) 2018-02-17 2023-10-05 好中球調節物質と免疫チェックポイントの調節物質の組み合わせを使用したがん処置

Country Status (6)

Country Link
US (1) US20200405719A1 (enExample)
EP (1) EP3752528A4 (enExample)
JP (2) JP2021515032A (enExample)
CN (1) CN112424222A (enExample)
CA (1) CA3091373A1 (enExample)
WO (1) WO2019161320A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024009886A (ja) * 2018-02-17 2024-01-23 アポロミクス インコーポレイテッド 好中球調節物質と免疫チェックポイントの調節物質の組み合わせを使用したがん処置

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4142715A4 (en) * 2020-04-26 2024-05-15 Apollomics Inc. NEW PHARMACEUTICAL FORMULATION FOR C-MET INHIBITOR
WO2021244551A1 (zh) * 2020-06-02 2021-12-09 正大天晴药业集团股份有限公司 c-Met激酶抑制剂和抗PD-L1抗体的联用药物组合物
CN116490507A (zh) 2020-09-10 2023-07-25 薛定谔公司 用于治疗癌症的杂环包缩合cdc7激酶抑制剂
CN113105436B (zh) * 2021-04-20 2022-07-01 西格莱(苏州)生物医药有限公司 吡唑类化合物的制备方法及其中间体
MX2023012434A (es) * 2021-04-21 2024-02-08 Apollomics Inc Diagnostico y tratamiento de cancer usando inhibidor de c-met.
WO2023172629A2 (en) * 2022-03-08 2023-09-14 Brown University Anticancer maleimide derivatives for use with immune checkpoint blockade
AU2024408812A1 (en) * 2023-12-21 2026-07-30 11949098 Canada Inc. (Nuredco) C/O Jean I. Tchervenkov Method of prognosis and monitoring of cancer patient and of determining immunological status of a subject

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015526486A (ja) * 2012-09-03 2015-09-10 クラウン バイオサイエンス インコーポレイテッド（台湾） 抗がん剤としての高選択性ｃ−Ｍｅｔ阻害剤
WO2017058780A1 (en) * 2015-09-30 2017-04-06 Merck Patent Gmbh Combination of a pd-1 axis binding antagonist and an alk inhibitor for treating alk-negative cancer
JP2017523786A (ja) * 2014-08-05 2017-08-24 シービー セラピューティックス インコーポレイテッド 抗ｐｄ−ｌ１抗体
JP2017530722A (ja) * 2014-07-22 2017-10-19 シービー セラピューティックス インコーポレイテッド 抗ｐｄ−１抗体
JP2017537112A (ja) * 2014-12-04 2017-12-14 ヤンセン ファーマシューティカ エンヴェー キナーゼモジュレーターとしての重水素化トリアゾロピリダジン

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101050829B1 (ko) * 2008-10-02 2011-07-20 서울대학교산학협력단 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제
EP3122900A1 (en) * 2014-03-24 2017-02-01 F. Hoffmann-La Roche AG Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
KR20170066546A (ko) * 2014-10-03 2017-06-14 노파르티스 아게 조합 요법
DK3294770T4 (da) * 2015-05-12 2024-05-21 Hoffmann La Roche Terapeutiske og diagnostiske fremgangsmåder til cancer
CN108697794A (zh) * 2015-12-17 2018-10-23 诺华股份有限公司 C-met抑制剂和抗pd-1抗体分子的组合及其用途
EP3752528A4 (en) * 2018-02-17 2021-11-03 Apollomics Inc. CANCER TREATMENT USING A COMBINATION OF A NEUTROPHIL MODULATOR WITH AN IMMUNE CHECKPOINT MODULATOR
WO2021244551A1 (zh) * 2020-06-02 2021-12-09 正大天晴药业集团股份有限公司 c-Met激酶抑制剂和抗PD-L1抗体的联用药物组合物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015526486A (ja) * 2012-09-03 2015-09-10 クラウン バイオサイエンス インコーポレイテッド（台湾） 抗がん剤としての高選択性ｃ−Ｍｅｔ阻害剤
JP2017530722A (ja) * 2014-07-22 2017-10-19 シービー セラピューティックス インコーポレイテッド 抗ｐｄ−１抗体
JP2017523786A (ja) * 2014-08-05 2017-08-24 シービー セラピューティックス インコーポレイテッド 抗ｐｄ−ｌ１抗体
JP2017537112A (ja) * 2014-12-04 2017-12-14 ヤンセン ファーマシューティカ エンヴェー キナーゼモジュレーターとしての重水素化トリアゾロピリダジン
WO2017058780A1 (en) * 2015-09-30 2017-04-06 Merck Patent Gmbh Combination of a pd-1 axis binding antagonist and an alk inhibitor for treating alk-negative cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
IMMUNITY, vol. 47, JPN6023002158, 2017, pages 789 - 802, ISSN: 0005209406 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024009886A (ja) * 2018-02-17 2024-01-23 アポロミクス インコーポレイテッド 好中球調節物質と免疫チェックポイントの調節物質の組み合わせを使用したがん処置

Also Published As

Publication number Publication date
CA3091373A1 (en) 2019-08-22
CN112424222A (zh) 2021-02-26
JP2024009886A (ja) 2024-01-23
EP3752528A4 (en) 2021-11-03
WO2019161320A1 (en) 2019-08-22
EP3752528A1 (en) 2020-12-23
US20200405719A1 (en) 2020-12-31

Similar Documents

Publication Publication Date Title
JP2024009886A (ja) 好中球調節物質と免疫チェックポイントの調節物質の組み合わせを使用したがん処置
Rossi et al. A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer
JP7482180B2 (ja) 癌のための併用療法
AU2007213920B2 (en) Treatment of metastatic breast cancer
US20220296658A1 (en) Methods of treating bladder cancer
JP2024009803A (ja) Ｈｅｒ２二量体化阻害剤ペルツズマブの使用及びペルツズマブを含む製造品
JP2022082565A (ja) がんを処置するための方法
KR20200119834A (ko) 항-cd47 및 항-cd20 항체를 이용한 항암 섭생
JP2019515916A (ja) グロボシリーズの抗原を介した免疫活性化又は免疫調節によるがん免疫療法
US11397184B2 (en) Selection of patients for combination therapy
Dickinson et al. Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma
BR112017028287A2 (en) COMBINATION OF THE HDAC INHIBITOR AND ANTICORPIDE ANTI-PD- L1 FOR CANCER TREATMENT
Wen et al. A Paradigm of Cancer Immunotherapy Based on 2-[18F] FDG and Anti–PD-L1 mAb Combination to Enhance the Antitumor Effect
JP2022553234A (ja) 免疫チェックポイント阻害剤と組み合わせた免疫調節ｉｌ－２剤
CN109153722A (zh) 用于治疗癌症的方法
US20220160718A1 (en) Compositions and methods of treating cancer
KR20200061382A (ko) 암을 치료하기 위한 조성물 및 방법
JP5889335B2 (ja) 癌治療用医薬組成物
Shablak et al. A case of fatal cetuximab-induced interstitial lung disease during the first weeks of treatment
AU2019266231B2 (en) Selection of patients for combination therapy
Bilen et al. Neoadjuvant cabozantinib restores CD8+ T cells in patients with locally advanced non-metastatic clear cell renal cell carcinoma: A phase 2 trial
Beyaert et al. Translational investigations in the HN1901 phase II window-of-opportunity study investigating the biological activity of an IDO1 (IO102) and PD-L1 (IO103) immune-modulatory peptide cancer vaccines in squamous cell carcinoma of the head and neck
HK40096805A (en) Selection of patients for combination therapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201021

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220216

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230424

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230606

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231005

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20231122

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20231208

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20250823